Recombinant Human Antibody (CT149) is capable of binding to IAV HA, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-IAV HA mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-IAV HA mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition. This antibody is found to neutralize all tested group 2 and some group 1 influenza A viruses by inhibiting low pH-induced, HA-mediated membrane fusion.
Figure 1 Recombinant Human Anti-IAV HA Antibody (PABL-213) in SDS-PAGE
SDS-PAGE analysis of PABL-213 in non-reduced (Lane 1, 2 μg) and β-mercaptoethanol-reduced (Lane 2, 2 μg) conditions.
Figure 2 Recombinant Human Anti-IAV HA Antibody (PABL-213) in HPLC
The purity of PABL-213 was greater than 95% as determined by SEC-HPLC.
Figure 3 Anti-IAV HA Recombinant Antibody (PABL-213) in ELISA
ELISA analysis of PABL-213 was performed by coating with Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag). Then blocked with BSA and incubated with PABL-213. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 4 Anti-IAV HA Recombinant Antibody (PABL-213) in ELISA
ELISA analysis of PABL-213 was performed by coating with Influenza A H3N2 (A/Victoria/210/2009) Hemagglutinin / HA Protein (His Tag). Then blocked with BSA and incubated with PABL-213. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 5 Anti-IAV HA Recombinant Antibody (PABL-213) in WB
Western blot analysis of PABL-213 was performed with Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with PABL-213 and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.
Lane 1: Reduced antigen (0.8 μg)
Figure 6 Anti-IAV HA Recombinant Antibody (PABL-213) in WB
Western blot analysis of PABL-213 was performed with Influenza A H3N2 (A/Victoria/210/2009) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with PABL-213 and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.
Lane 1: Reduced antigen (0.8 μg)
Figure 7 Anti-IAV HA Recombinant Antibody (PABL-213) in WB
Western blot analysis of PABL-213 was performed with Influenza A H2N2 (A/Japan/305/1957) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with PABL-213 and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.
Lane 1: Reduced antigen (0.8 μg)
Figure 8 Anti-IAV HA Recombinant Antibody (PABL-213) in DB
Dot Blot analysis of PABL-213 was performed by coating with Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag).
PABL-213 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)
Figure 9 Anti-IAV HA Recombinant Antibody (PABL-213) in DB
Dot Blot analysis of PABL-213 was performed by coating with Influenza A H3N2 (A/Victoria/210/2009) Hemagglutinin / HA Protein (His Tag).
PABL-213 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)
Park, Jae-Keun, et al. "Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model." Nature medicine 26.8 (2020): 1240-1246.
This study investigates the selection of an HA stalk antibody-escape mutant virus in human influenza challenge participants. The researchers focused on a well-characterized influenza A virus stock containing a mixed population of wild-type and mutant viruses with a nonsynonymous single-nucleotide polymorphism (SNP) in the HA stalk (A388V). They analyzed pre-existing anti-HA stalk antibody levels and post-challenge viral shedding in participants, revealing that higher pre-challenge anti-HA stalk antibody titers were associated with the selection of the mutant virus. The study found that the A388V mutation conferred resistance to some broadly neutralizing monoclonal antibodies (bNAbs) and was rapidly selected under immune pressure, highlighting a potential challenge for HA-stalk-targeting universal influenza vaccines.
Creative Biolabs provided several key reagents for this research, including the broadly neutralizing monoclonal antibodies CR9114 (Cat#: PABX-119), FI6V3 (Cat#: PABL-214), and CT149 (Cat#: PABL-213). These antibodies were essential for evaluating the binding and neutralization characteristics of the mutant and wild-type viruses. The specific contributions of these antibodies were crucial for understanding the structural changes and resistance mechanisms conferred by the A388V mutation, thereby aiding in the comprehensive analysis of HA stalk antibody escape and its implications for vaccine development.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
PABL-214 | Recombinant Human Anti-IAV HA Antibody (FI6V3) | WB, IHC, FuncS | IgG |
PABL-215 | Recombinant Human Anti-IAV HA Antibody (FLD194) | Neut, FuncS | IgG |
PABL-216 | Recombinant Mouse Anti-IAV HA Antibody (GC0587) | ELISA, FuncS | IgG |
PABL-217 | Recombinant Human Anti-IAV HA Antibody (GC0757 ) | WB, ELISA, Neut, FuncS | IgG |
PABL-218 | Recombinant Human Anti-IAV HA Antibody (H2526) | Neut, FuncS | IgG |
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# PABL-213, RRID: AB_3111638)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.